ReShape Lifesciences Inc. presented data on its proprietary Diabetes Bloc-Stim Neuromodulation(TM) (DBSN(TM) device in an e-poster at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual Meeting, being held in Las Vegas, NV, June 25 - 29, 2023. The Diabetes Bloc-StimNeuromodulation(TM)) device is a novel therapeutic concept that is implanted minimally invasively and delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The DBSN(TM) system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation.

The DBSNâ„¢ system utilizes a proprietary, reversable and adjustable electrical blockade felt to be key to the future of personalized medicine. The DBSN(TM) system is superior to both standalone stimulation of the vagus nerve that has shown mixed results, and vagus nerve ligation that has undesirable effects.